Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.47 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.47 |
| ▸ | PPARG | P37231 | 2/20 | 0.44 |
| ▸ | PPARD | Q03181 | 2/20 | 0.44 |
| ▸ | PPARA | Q07869 | 2/20 | 0.44 |
| ▸ | CFTR | P13569 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | POLQ | O75417 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24875503 | 0.84 | EPHX2 (0.43) | KDM4EPOLQNOTUMALDH1A1TDP1 | |
| SCHEMBL15524132 | 0.83 | PPARG (0.44) | PPARGPPARDPPARACFTRMAPT | |
| SCHEMBL2946105 | 0.83 | HTT (0.53) | MAPTPOLQNOTUMLMNAALDH1A1 | |
| SCHEMBL20576236 | 0.83 | HDAC3 (0.53) | PPARGPPARDPPARAMAPTHDAC3 | |
| SCHEMBL29331520 | 0.83 | RXRA (0.51) | PPARGPPARDPPARACFTRMAPT | |
| SCHEMBL14420158 | 0.82 | ALDH1A1 (0.43) | PPARGPPARDPPARAKDM4EMEN1 | |
| SCHEMBL6864787 | 0.82 | CES2 (0.55) | CES2SRD5A2KDM4EPOLQMEN1 | |
| SCHEMBL27757329 | 0.81 | ANO1 (0.49) | PPARGPPARDPPARACFTRMAPT | |
| SCHEMBL18075562 | 0.81 | IDO1 (0.50) | PPARGPPARDPPARACFTRMAPT | |
| SCHEMBL5574328 | 0.80 | CES2 (0.53) | CES2SRD5A2KDM4EPOLQALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1805141-B1 | PIPERIDINES AND RELATED COMPOUNDS FOR TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME (GB) | 2010-01-20 | — | — | EP | disclosed |
| US-7638629-B2 | Piperidines and related compounds for treatment of alzheimer's disease | Merck Sharp & Dohme Ltd, (GB) | 2009-12-29 | — | — | US | disclosed |
| US-20080021043-A1 | Piperidines and Related Compounds for Treatment of Alzheimer's Disease | MERCK SHARP & DOHME LTD. (GB) | 2008-01-24 | — | — | US | disclosed |
| EP-1805141-A1 | PIPERIDINES AND RELATED COMPOUNDS FOR TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME LTD. (GB) | 2007-07-11 | — | — | EP | disclosed |
| WO-2006043064-A1 | PIPERIDINES AND RELATED COMPOUNDS FOR TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME LIMITED (GB) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021043-A1 | Piperidines and Related Compounds for Treatment of Alzheimer's Disease | PSEN1, PSEN2, APP | CES2 1340/4885SRD5A2 4379/4885PPARG 1182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.